By admin 
When Defense Secretary Pete Hegseth announced on Wednesday that the Department of Defense (DoD) would implement a mandatory testosterone screening program for all service members aged 30 and older, it signaled a radical shift in military health policy and a departure from established medical norms. For those who study men’s health and the intricacies of population-level screening, this directive raises profound questions regarding the medical, ethical, and logistical future of the U.S. Armed Forces. While the initiative is presented as a measure to ensure the vitality and readiness of the fighting force, the widespread rollout of such a program may trigger a cascade of unintended consequences. As a practicing urologist and health outcomes researcher who has extensively studied the implementation of screening tests within military populations, I believe it is imperative to weigh the potential benefits of this policy against the substantial risks and the scientific uncertainties that surround testosterone supplementation.
The biological foundation of this discussion lies in the hypothalamic-pituitary-gonadal (HPG) axis, a sophisticated feedback loop that regulates the production of testosterone. This hormone is not merely a marker of masculinity; it is a critical chemical messenger that influences the development of reproductive organs, the onset of puberty, bone density, muscle mass, and behavioral traits such as libido and aggression. However, testosterone levels are not static; they are highly sensitive to external and internal factors. In the high-stress environment of military service, factors such as sleep deprivation, chronic stress, intense physical exertion, and dietary variations can all suppress the HPG axis. Furthermore, it is a well-documented physiological fact that testosterone levels naturally decline as men age, typically at a rate of about 1% to 2% per year after the age of 30. Distinguishing between this natural "andropause" and a pathological deficiency—often referred to as hypogonadism—is one of the most complex challenges in modern urology.
The decision to mandate screening for a hormone that naturally fluctuates and declines with age is a medical experiment on a massive scale. Traditionally, population-level screening is reserved for conditions where early detection significantly improves outcomes, such as certain cancers or hypertension. However, the American Urological Association (AUA) and the Endocrine Society have long cautioned against routine, asymptomatic screening for low testosterone. Their guidelines emphasize that testosterone therapy should be reserved for men who exhibit both low serum testosterone levels and clinical symptoms of deficiency, such as profound fatigue, sexual dysfunction, or significant loss of bone mass. By mandating tests for all service members over 30, regardless of whether they feel "unwell," the DoD is effectively ignoring these clinical safeguards.
To understand the gravity of this policy, one must look at the explosive growth of the testosterone replacement therapy (TRT) market. In the late 1980s, global sales of testosterone products were a modest $18 million. By 2025, that figure is projected to reach nearly $2 billion. This meteoric rise has not been driven solely by medical necessity; it has been fueled by a multi-billion-dollar direct-to-consumer marketing machine, the rise of "wellness" influencers, and a cultural obsession with "optimization." In many corners of the internet, testosterone is marketed as a panacea for everything from brain fog to career stagnation. While some men benefit immensely from appropriately managed TRT, others fall victim to loosely regulated online clinics that prescribe testosterone without adequate oversight, leading to supra-physiological levels that can be dangerous. The DoD’s new policy risks institutionalizing this "optimization" culture within the military, potentially pressuring service members to seek supplementation to maintain a competitive edge or to meet a perceived standard of "masculinity."
The clinical risks associated with testosterone supplementation are significant and well-documented in the medical literature. In 2010, a landmark study known as the TOM (Testosterone in Older Men with Mobility Limitations) trial had to be halted prematurely because the group receiving testosterone therapy experienced a significantly higher rate of major adverse cardiac events, including heart attacks and strokes, compared to the placebo group. While a more recent 2023 study, the TRAVERSE trial, offered some reassurance by showing that TRT did not increase the risk of major cardiac events over the short term in a specific cohort, it revealed other troubling side effects. Participants on testosterone therapy showed a higher incidence of acute kidney injury, atrial fibrillation (a dangerous heart rhythm disorder), and pulmonary embolism (blood clots in the lungs).
My own research, which utilized data from the military’s health insurance system (TRICARE), has further illuminated these risks within the specific context of the service member population. In studies supported by the DoD, my colleagues and I found that military beneficiaries using testosterone supplementation had higher rates of kidney stones and a significant increase in the diagnosis of obstructive sleep apnea. While our data also showed some improvements in cardiovascular outcomes in certain subsets, the overall picture is one of complexity. Testosterone is not a "free lunch"; every benefit to muscle mass or mood comes with a potential metabolic or physiological cost.
One of the most critical, yet often overlooked, side effects of testosterone supplementation is its impact on fertility. When a man takes exogenous (external) testosterone, it triggers a negative feedback loop that tells the brain to stop producing the hormones that stimulate the testicles. This leads to a decrease in testicle size and, more importantly, a dramatic drop in sperm count, often leading to temporary or even permanent infertility. Given that many service members in their 30s are still in their peak reproductive years and may be planning to start or expand their families, the widespread use of TRT could have a profound impact on the personal lives of thousands of military families. Both the Endocrine Society and the AUA specifically advise against the use of testosterone in men who desire future fertility, a recommendation that stands in direct tension with a policy that may encourage widespread supplementation.
The logistical challenge of implementing this mandate is equally daunting. A single testosterone test is rarely sufficient for a diagnosis. Testosterone levels peak in the morning and can be temporarily suppressed by a single night of poor sleep or a high-carbohydrate meal. Therefore, clinical guidelines require at least two separate morning blood draws, along with the measurement of other markers such as Luteinizing Hormone (LH) and Prolactin, to accurately diagnose the cause of low levels. Furthermore, once a service member begins TRT, they require lifelong monitoring. This includes regular blood work to check hematocrit levels (the percentage of red blood cells), as testosterone can thicken the blood and increase the risk of stroke, as well as monitoring for prostate health and liver function. Scaling this level of personalized, high-touch medical care to the hundreds of thousands of individuals in the DoD health system will place an immense burden on military medical resources.
Moreover, the ethical implications of this policy cannot be ignored. While Secretary Hegseth stated that the decision to take supplements would remain with the individual service member, the "voluntary" nature of medical treatment in a hierarchical military structure is often complicated. If a service member is told by their commanding organization that their "levels are low," they may feel a professional obligation to "fix" the issue to remain "mission-ready." This creates a potential for coercion, where soldiers might feel pressured to accept a lifelong medical intervention for a condition they didn’t know they had and which might not actually be impacting their performance.
There is also the question of what this means for the definition of "readiness." By focusing on a single hormonal marker, the DoD may be oversimplifying the complex reality of human performance. Strength, endurance, and mental resilience are the result of training, discipline, and holistic health—not just a number on a lab report. There is a risk that this policy will prioritize hormonal "optimization" over proven methods of readiness, such as improving sleep hygiene, mental health support, and injury prevention.
In conclusion, the Department of Defense’s move to mandate testosterone screening for service members 30 and older is a radical departure from traditional medical practice. It is an experiment that lacks a clear precedent and ignores the cautious recommendations of major medical societies. While the goal of a more robust and energetic fighting force is laudable, the path to achieving it through mass hormonal screening is fraught with peril. From the increased risks of blood clots and kidney injury to the potentially devastating impact on male fertility, the costs of widespread testosterone supplementation are high. For the health and well-being of those who serve, it is essential that this program be implemented with the highest level of clinical rigor, ensuring that every service member receives individualized counseling and that the long-term health outcomes of the force are monitored with transparency and scientific integrity. Without such safeguards, this "novel experiment" could lead to a health crisis within the very ranks it seeks to strengthen.
